744 Assessment of safety and immunologic activity of nemvaleukin alfa in patients with advanced soli...
744 Assessment of safety and immunologic activity of nemvaleukin alfa in patients with advanced solid tumors treated with less frequent intravenous dosing (ARTISTRY-3)
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundNemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel engineered cytokine designed to selectively bind the intermediate-affinity interleukin-2 receptor, preferentially expanding antitumor CD8+ T and natural killer (NK) cells with minimal effect on immunosuppressive regulatory T cells (Tregs).1 In ARTISTRY-1, intravenous (IV) nemvaleukin on...
Alternative Titles
Full title
744 Assessment of safety and immunologic activity of nemvaleukin alfa in patients with advanced solid tumors treated with less frequent intravenous dosing (ARTISTRY-3)
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_284c76dfd06d44da802dee78a7b00d2a
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_284c76dfd06d44da802dee78a7b00d2a
Other Identifiers
E-ISSN
2051-1426
DOI
10.1136/jitc-2023-SITC2023.0744
